{"nctId":"NCT00473343","briefTitle":"Metvix PDT in Participant With \"High Risk\" Basal Cell Carcinoma","startDateStruct":{"date":"2000-09","type":"ACTUAL"},"conditions":["Basal Cell Carcinoma"],"count":102,"armGroups":[{"label":"Metvix® PDT","type":"EXPERIMENTAL","interventionNames":["Drug: Metvix® cream"]}],"interventions":[{"name":"Metvix® cream","otherNames":["Methyl 5-aminolevulinate hydrochloride"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of BCC lesions verified by histology (2-3 mm punch biopsy)\n* Males or females above 18 years of age.\n* Written informed consent. AND\n\nParticipants with high risk of surgical complications due to:\n\n* Anticoagulant medication or bleeding disorders\n* Cardiac risk factors\n* Anaesthetic contraindications\n* Poor surgical compliance because of participant refusal, dementia, or inability to perform wound care.\n\nOR\n\n• Participants with \"high-risk BCC lesion(s). A \"high-risk\" BCC lesion is defined as:\n\nA large BCC lesion with the largest diameter:\n\n* Equal to or greater than 15 mm on extremities, except below the knees, where largest diameter should be equal to or greater than 10 mm\n* Equal to or greater than 20 mm on the trunk\n* Equal to or greater than 15 mm in the face, or A lesion in the mid-face region (H-zone according to Swanson) or on the ear In participants with more then 6 eligible lesions, the 6 lesions to be treated was randomly chosen.\n\nExclusion Criteria:\n\n* Prior treatment of the lesion within 4 weeks.\n* A pure morpheaform and/or highly infiltrated lesion assessed clinically and/or by histology. A mixed nodular/morpheaform lesion which is not highly infiltrated (clinically) may be included.\n* Participant with porphyria.\n* Pigmented lesions.\n* Known allergy to Metvix® or a similar compound.\n* Participation in another clinical study either concurrently or within the last 30 days\n* Participant with Gorlin's syndrome.\n* Participant with Xeroderma pigmentosum\n* Pregnant or breast-feeding (all women of child-bearing potential must document a negative pregnancy test and use contraception during the treatments and for at least one month thereafter).\n* Conditions associated with a risk of poor protocol compliance.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle","description":"Patient Complete Response (CR) was defined as 100 percentage of the lesions within the participant having negative findings for nodular basal cell carcinoma (BCC) in the histological examination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Lesion With Complete Response 3 Months After Last Metvix PDT Cycle","description":"Complete response was defined as no clinically visible BCC lesions in the treatment area.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Cosmetic Outcome Assessed by Investigator 3 Months After the Last Metvix PDT Cycle","description":"Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Cosmetic Outcome Assessed by Participants 3 Months After the Last Metvix PDT Cycle","description":"Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The participants graded the cosmetic outcome as:\n\nexcellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin fair: slight to moderate occurrence of scarring, atrophy or induration poor: extensive occurrence of scarring, atrophy or induration.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrence Rate in Complete Clearance Group","description":"Recurrence rate in complete clearance(CC) group was analyzed.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Cosmetic Outcome Assessed by Investigator 24, 36, 48, and 60 Months After the Last Metvix PDT Cycle","description":"Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\nexcellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin fair: slight to moderate occurrence of scarring, atrophy or induration poor: extensive occurrence of scarring, atrophy or induration.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":102},"commonTop":["Surgical intervention","Basel cell carcinoma","Headache","Nausea","Pain"]}}}